WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Broker-Dealer
  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Investment Adviser
  • Israel
  • Latin America
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • Decarbonization Strategies
  • Energy Regulation and Competition
  • Project Development and Transactions
  • Project Finance and Tax Equity
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • National Security
  • Payments
  • Privacy and Cybersecurity
  • Strategic Risk and Crisis Management

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Merger Clearance
  • Antitrust Litigation
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • FoodTech and AgTech
  • Fintech and Financial Services
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Semiconductors
  • Software

  • Offices
  • Events
  • Pro Bono
  • Community
  • Our Diversity
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Beijing
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • SOMA
  • Washington, D.C.
  • Wilmington, DE

  • Law Students + Recent Graduates
  • Experienced Attorneys
  • Patent Agents
  • Professional Staff
  • Alternative Legal Careers
  • Contact Recruiting
Rui Ke
Associate
Corporate
New York
rui.ke@wsgr.com

D212-453-2809

Download vCard
Open PDF

Rui (Ruijia) Ke is an associate in the New York office of Wilson Sonsini Goodrich & Rosati, where she focuses on representation of public and private technology companies at all stages of growth. She also focuses on corporate and securities law, including general corporate representation, venture capital financings, mergers and acquisitions, and public offerings.

While attending law school, Rui worked at the Duke Law School Start-Up Ventures Clinic.

Experience

Rui (Ruijia) Ke is an associate in the New York office of Wilson Sonsini Goodrich & Rosati, where she focuses on representation of public and private technology companies at all stages of growth. She also focuses on corporate and securities law, including general corporate representation, venture capital financings, mergers and acquisitions, and public offerings.

While attending law school, Rui worked at the Duke Law School Start-Up Ventures Clinic.

Education
  • J.D., Duke University School of Law, 2019Cum Laude; Symposium Editor, Law & Contemporary Problems
  • LL.B., China University of Political Science and Law, 2015
Admissions
  • Qualified in People's Republic of China
  • State Bar of New York
Credentials
Education
  • J.D., Duke University School of Law, 2019Cum Laude; Symposium Editor, Law & Contemporary Problems
  • LL.B., China University of Political Science and Law, 2015
Admissions
  • Qualified in People's Republic of China
  • State Bar of New York
Focus Areas
  • Corporate
Recent Insights
Client Highlights
Wilson Sonsini Advises ONI on $75 Million Series B
On January 20, 2022, ONI, a biotechnology company democratizing the ability to observe single molecules in living cells with its desktop Nanoimager microscopy platform, announced the closing of a $75 million Series B funding round. The round was led by ARCH Venture Partners and Casdin Capital with participation from Section 32, ARTIS Ventures, Vertical Venture Partners, Axon Ventures, and private investors, including Paul Conley. Existing investors, including Oxford Science Enterprises, also participated in the round. Wilson Sonsini Goodrich & Rosati advised ONI on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Verana Health on $150 Million Series E Funding
On January 14, 2022, Verana Health, a digital health company that delivers quality drug lifecycle and medical practice insights from an exclusive real-world data network, announced a $150 million Series E funding round led by Johnson & Johnson Innovation and Novo Growth, the growth-stage investment arm of Novo Holdings. Existing Verana Health investors GV (formerly Google Ventures), Casdin Capital, and Brook Byers also joined the round, as well as notable new investors, including the Merck Global Health Innovation Fund, THVC, and Breyer Capital. Verana Health plans to use the proceeds of the investment to advance its life sciences product and service strategy across the drug lifecycle, further enhance its value proposition to healthcare providers participating in its real-world data network, and expand its data footprint through medical society and strategic partnerships.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Employee Login
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2023 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.